Institute for Molecular Cardiovascular Research, RWTH Aachen University, Germany.
Curr Stem Cell Res Ther. 2013 Jul;8(4):278-83. doi: 10.2174/1574888x11308040003.
Modern life styles have made cardiovascular disease the leading cause of morbidity and mortality worldwide. Although current treatments substantially ameliorate patients' prognosis after MI, they cannot restore the affected tissue or entirely re-establish organ function. Therefore, the main goal of modern cardiology should be to design strategies to reduce myocardial necrosis and optimize cardiac repair following MI. Cell-based therapy was considered a novel and potentially new strategy in regenerative medicine; however, its clinical implementation has not yielded the expected results. Chemokines seem to increase the efficiency of cell-therapy and may represent a reliable method to be exploited in the future. This review surveys current knowledge of cell therapy and highlights key insights into the role of chemokines in stem cell engraftment in infarcted myocardium and their possible clinical implications.
现代生活方式使心血管疾病成为全球发病率和死亡率的主要原因。尽管目前的治疗方法大大改善了心肌梗死后患者的预后，但它们不能修复受影响的组织或完全重建器官功能。因此，现代心脏病学的主要目标应该是设计策略来减少心肌坏死，并优化心肌梗死后的心脏修复。细胞疗法被认为是再生医学中的一种新的潜在策略；然而，其临床实施并未产生预期的结果。趋化因子似乎可以提高细胞治疗的效率，并且可能是未来可以利用的可靠方法。本综述总结了细胞治疗的最新知识，并强调了趋化因子在干细胞植入梗死心肌中的作用及其可能的临床意义的关键见解。
